Symbols / EWTX Stock $33.09 -2.71% Edgewise Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
EWTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Kevin Koch Ph.D.
Exch · Country NMS · United States
Market Cap 3.56B
Enterprise Value 3.06B
Income -176.01M
Sales —
FCF (ttm) -90.52M
Book/sh 4.59
Cash/sh 4.64
Employees 154
Insider 10d —
IPO Mar 26, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -14.19
PEG —
P/S —
P/B 7.21
P/C —
EV/EBITDA -15.52
EV/Sales —
Quick Ratio 22.16
Current Ratio 22.61
Debt/Eq 0.77
LT Debt/Eq —
EPS (ttm) -1.66
EPS next Y -2.33
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -25.64%
ROE -38.14%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 107.59M
Shs Float 67.94M
Insider Own 0.45%
Instit Own 113.57%
Short Float 13.32%
Short Ratio 10.34
Short Interest 10.13M
52W High 39.96
vs 52W High -17.19%
52W Low 12.15
vs 52W Low 172.35%
Beta 0.25
Impl. Vol. 46.69%
Rel Volume 0.96
Avg Volume 1.03M
Volume 989.08K
Target (mean) $43.67
Tgt Median $45.50
Tgt Low $20.00
Tgt High $52.00
# Analysts 12
Recom Buy
Prev Close $34.01
Price $33.09
Change -2.71%
About

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$43.67
Mean price target
2. Current target
$33.09
Latest analyst target
3. DCF / Fair value
$-15.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.09
Low
$20.00
High
$52.00
Mean
$43.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 main JP Morgan Overweight → Overweight $45
2026-03-17 reit Wedbush Outperform → Outperform $32
2026-02-27 main Evercore ISI Group Outperform → Outperform $45
2025-11-14 main JP Morgan Overweight → Overweight $34
2025-11-07 main RBC Capital Outperform → Outperform $50
2025-11-07 main Wedbush Outperform → Outperform $32
2025-09-25 init Goldman Sachs — → Neutral $20
2025-08-19 main JP Morgan Overweight → Overweight $30
2025-08-08 main RBC Capital Outperform → Outperform $49
2025-06-30 init HC Wainwright & Co. — → Buy $42
2025-06-05 reit RBC Capital Outperform → Outperform $48
2025-05-16 main JP Morgan Overweight → Overweight $40
2025-05-09 main RBC Capital Outperform → Outperform $48
2025-04-21 main Wedbush Outperform → Outperform $43
2025-04-03 main RBC Capital Outperform → Outperform $52
2025-04-03 down Scotiabank Sector Outperform → Sector Perform $14
2025-04-02 main Piper Sandler Overweight → Overweight $51
2025-03-07 init Scotiabank — → Sector Outperform $50
2025-03-04 reit RBC Capital Outperform → Outperform $56
2025-01-22 init Stifel — → Hold $30
News
RSS: Latest EWTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-05 DONOVAN JOANNE M Officer — 55,230 $31.29 $1,736,163
2026-05-05 DONOVAN JOANNE M Officer — 50,000 $7.08 $354,000
2026-04-01 FOX JONATHAN C Director — 339 $0.00 $0
2026-04-01 DONOVAN JOANNE M Officer — 28,662 $32.31 $926,095
2026-04-01 DONOVAN JOANNE M Officer — 28,662 $7.08 $202,927
2026-03-31 DONOVAN JOANNE M Officer — 21,338 $32.12 $685,308
2026-03-31 DONOVAN JOANNE M Officer — 21,338 $7.08 $151,073
2026-03-27 DONOVAN JOANNE M Officer — 16,358 $30.98 $506,735
2026-01-21 EDRIS BADREDDIN Director — 115,471 $29.44 $3,399,466
2026-01-21 EDRIS BADREDDIN Director — 115,471 $0.39 $170,264
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
191.41
+20.51%
158.83
+38.89%
114.36
+59.59%
71.66
Research And Development
151.39
+19.24%
126.97
+39.67%
90.91
+68.24%
54.03
Selling General And Administration
40.02
+25.58%
31.87
+35.88%
23.45
+33.05%
17.63
General And Administrative Expense
40.02
+25.58%
31.87
+35.88%
23.45
+33.05%
17.63
Other Gand A
40.02
+25.58%
31.87
+35.88%
23.45
+33.05%
17.63
Total Expenses
191.41
+20.51%
158.83
+38.89%
114.36
+59.59%
71.66
Operating Income
-191.41
-20.51%
-158.83
-38.89%
-114.36
-59.59%
-71.66
Total Operating Income As Reported
-191.41
-20.51%
-158.83
-38.89%
-114.36
-59.59%
-71.66
EBITDA
-189.14
-20.82%
-156.54
-38.99%
-112.62
-58.36%
-71.12
Normalized EBITDA
-189.14
-20.82%
-156.54
-38.99%
-112.62
-58.36%
-71.12
Reconciled Depreciation
2.27
-1.05%
2.29
+32.22%
1.73
+221.93%
0.54
EBIT
-191.41
-20.51%
-158.83
-38.89%
-114.36
-59.59%
-71.66
Net Income
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Pretax Income
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Net Non Operating Interest Income Expense
23.61
-5.63%
25.02
+76.26%
14.19
+253.26%
4.02
Net Interest Income
23.61
-5.63%
25.02
+76.26%
14.19
+253.26%
4.02
Interest Income Non Operating
23.61
-5.63%
25.02
+76.26%
14.19
+253.26%
4.02
Interest Income
23.61
-5.63%
25.02
+76.26%
14.19
+253.26%
4.02
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Net Income From Continuing Operation Net Minority Interest
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Net Income From Continuing And Discontinued Operation
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Net Income Continuous Operations
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Normalized Income
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Net Income Common Stockholders
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Diluted EPS
—
-0.42
+73.25%
-1.57
-406.45%
-0.31
Basic EPS
—
-0.42
+73.25%
-1.57
-406.45%
-0.31
Basic Average Shares
—
94.72
+48.64%
63.72
+0.78%
63.23
Diluted Average Shares
—
94.72
+48.64%
63.72
+0.78%
63.23
Diluted NI Availto Com Stockholders
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
552.60
+13.51%
486.82
+43.17%
340.04
-7.37%
367.10
Current Assets
543.38
+14.28%
475.48
+45.41%
327.00
-8.40%
357.00
Cash Cash Equivalents And Short Term Investments
530.11
+12.75%
470.17
+47.67%
318.39
-9.53%
351.95
Cash And Cash Equivalents
61.15
+46.76%
41.67
-51.61%
86.10
+291.47%
21.99
Other Short Term Investments
468.96
+9.44%
428.50
+84.46%
232.30
-29.60%
329.95
Prepaid Assets
—
—
—
5.05
Other Current Assets
13.28
+149.88%
5.31
-38.25%
8.60
+70.31%
5.05
Total Non Current Assets
9.22
-18.67%
11.33
-13.07%
13.04
+29.06%
10.10
Net PPE
9.22
-16.74%
11.07
-12.75%
12.69
+28.82%
9.85
Gross PPE
15.99
+1.46%
15.76
+2.95%
15.31
+40.22%
10.92
Accumulated Depreciation
-6.77
-44.48%
-4.68
-79.09%
-2.62
-145.63%
-1.06
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.81
+0.00%
0.81
+3.73%
0.78
+176.87%
0.28
Construction In Progress
0.08
0.00
-100.00%
0.08
-98.91%
7.34
Other Properties
5.46
+2.88%
5.30
-7.27%
5.72
+73.49%
3.30
Leases
9.65
+0.00%
9.65
+10.52%
8.73
0.00
Other Non Current Assets
—
0.26
-24.71%
0.35
+38.65%
0.25
Total Liabilities Net Minority Interest
30.35
+9.95%
27.60
+30.16%
21.20
+4.02%
20.39
Current Liabilities
27.37
+14.71%
23.86
+42.27%
16.77
+1.12%
16.59
Payables And Accrued Expenses
13.93
+8.73%
12.81
+26.86%
10.10
-15.48%
11.95
Payables
6.01
+7.65%
5.58
+38.61%
4.03
-34.07%
6.11
Accounts Payable
6.01
+7.65%
5.58
+38.61%
4.03
-34.07%
6.11
Current Accrued Expenses
7.92
+9.56%
7.23
+19.07%
6.07
+3.96%
5.84
Pensionand Other Post Retirement Benefit Plans Current
12.43
+23.61%
10.06
+76.58%
5.70
+41.25%
4.03
Current Debt And Capital Lease Obligation
1.01
+1.81%
1.00
+1.63%
0.98
+61.18%
0.61
Current Capital Lease Obligation
1.01
+1.81%
1.00
+1.63%
0.98
+61.18%
0.61
Total Non Current Liabilities Net Minority Interest
2.98
-20.45%
3.74
-15.63%
4.43
+16.68%
3.80
Long Term Debt And Capital Lease Obligation
2.98
-20.45%
3.74
-15.63%
4.43
+16.68%
3.80
Long Term Capital Lease Obligation
2.98
-20.45%
3.74
-15.63%
4.43
+16.68%
3.80
Other Non Current Liabilities
—
—
—
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Common Stock Equity
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Capital Stock
0.01
+11.11%
0.01
+28.57%
0.01
+16.67%
0.01
Common Stock
0.01
+11.11%
0.01
+28.57%
0.01
+16.67%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
106.25
+12.03%
94.84
+34.61%
70.45
+11.38%
63.26
Ordinary Shares Number
106.25
+12.03%
94.84
+34.61%
70.45
+11.38%
63.26
Additional Paid In Capital
1,067.94
+27.54%
837.36
+48.60%
563.49
+14.38%
492.67
Retained Earnings
-546.37
-44.32%
-378.58
-54.67%
-244.76
-69.27%
-144.60
Gains Losses Not Affecting Retained Earnings
0.68
+61.19%
0.42
+324.24%
0.10
+107.31%
-1.35
Other Equity Adjustments
0.68
+61.19%
0.42
+324.24%
0.10
+107.31%
-1.35
Total Equity Gross Minority Interest
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Total Capitalization
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Working Capital
516.01
+14.26%
451.62
+45.58%
310.23
-8.87%
340.41
Invested Capital
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Total Debt
3.99
-15.77%
4.74
-12.50%
5.41
+22.82%
4.41
Capital Lease Obligations
3.99
-15.77%
4.74
-12.50%
5.41
+22.82%
4.41
Net Tangible Assets
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Tangible Book Value
522.26
+13.73%
459.22
+44.03%
318.83
-8.04%
346.72
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-143.82
-31.91%
-109.03
-18.58%
-91.95
-74.69%
-52.63
Cash Flow From Continuing Operating Activities
-143.82
-31.91%
-109.03
-18.58%
-91.95
-74.69%
-52.63
Net Income From Continuing Operations
-167.79
-25.40%
-133.81
-33.60%
-100.16
-48.08%
-67.64
Depreciation Amortization Depletion
2.27
-1.05%
2.29
+32.22%
1.73
+221.93%
0.54
Depreciation
2.27
-1.05%
2.29
+32.22%
1.73
+221.93%
0.54
Depreciation And Amortization
2.27
-1.05%
2.29
+32.22%
1.73
+221.93%
0.54
Stock Based Compensation
34.75
+40.63%
24.71
+40.73%
17.56
+60.75%
10.92
Change In Working Capital
-5.37
-152.03%
10.33
+762.05%
-1.56
-138.18%
4.09
Change In Prepaid Assets
-7.96
-341.89%
3.29
+192.65%
-3.55
-144.70%
-1.45
Change In Payables And Accrued Expense
3.34
-54.01%
7.26
+246.02%
2.10
-19.90%
2.62
Change In Accrued Expense
3.06
-44.46%
5.52
+152.12%
2.19
-14.86%
2.57
Change In Payable
0.27
-84.34%
1.74
+1988.04%
-0.09
-295.74%
0.05
Change In Account Payable
0.27
-84.34%
1.74
+1988.04%
-0.09
-295.74%
0.05
Change In Other Working Capital
—
—
—
1.24
Change In Other Current Liabilities
-0.75
-240.00%
-0.22
-111.54%
-0.10
-103.56%
2.92
Investing Cash Flow
-32.79
+82.24%
-184.66
-279.48%
102.89
+245.78%
-70.58
Cash Flow From Continuing Investing Activities
-32.79
+82.24%
-184.66
-279.48%
102.89
+245.78%
-70.58
Net PPE Purchase And Sale
-0.26
+80.49%
-1.31
+77.16%
-5.75
-3.59%
-5.55
Purchase Of PPE
-0.26
+80.49%
-1.31
+77.16%
-5.75
-3.59%
-5.55
Capital Expenditure
-0.26
+80.49%
-1.31
+77.16%
-5.75
-3.59%
-5.55
Net Investment Purchase And Sale
-32.53
+82.26%
-183.34
-268.78%
108.63
+267.04%
-65.03
Purchase Of Investment
-527.23
-10.52%
-477.06
-86.45%
-255.87
+12.49%
-292.39
Sale Of Investment
494.69
+68.43%
293.71
-19.42%
364.50
+60.32%
227.36
Financing Cash Flow
196.09
-21.33%
249.25
+368.82%
53.17
-58.99%
129.64
Cash Flow From Continuing Financing Activities
196.09
-21.33%
249.25
+368.82%
53.17
-58.99%
129.64
Net Common Stock Issuance
187.36
-21.65%
239.15
+354.50%
52.62
-59.26%
129.16
Proceeds From Stock Option Exercised
8.73
-15.84%
10.37
+1354.14%
0.71
-1.66%
0.72
Net Other Financing Charges
—
-0.26
-58.79%
-0.17
+34.26%
-0.25
Changes In Cash
19.48
+143.85%
-44.43
-169.31%
64.10
+897.42%
6.43
Beginning Cash Position
41.67
-51.61%
86.10
+291.47%
21.99
+41.29%
15.57
End Cash Position
61.15
+46.76%
41.67
-51.61%
86.10
+291.47%
21.99
Free Cash Flow
-144.07
-30.57%
-110.34
-12.95%
-97.69
-67.91%
-58.18
Amortization Of Securities
-7.67
+38.90%
-12.54
-31.82%
-9.52
-1652.67%
-0.54
Common Stock Issuance
187.36
-21.65%
239.15
+354.50%
52.62
-59.26%
129.16
Issuance Of Capital Stock
187.36
-21.65%
239.15
+354.50%
52.62
-59.26%
129.16
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category